Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAL-85-1 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0088347 | 0.0160 | 0.6258 | 0.0624 | 1.3592 | 0.0084516 | 0.99836 |
CAL-85-1 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0208 | -0.0232 | 0.0035 | 0.0000 | Inf | -0.61108 |
CAL-85-1 | Buparlisib | pan PI3K | PI3K/mTOR | 0.34255 | -0.3199 | 0.4420 | 0.1137 | 0.9213 | 0.69609 | 0.99686 |
CAL-85-1 | Pictilisib | pan PI3K | PI3K/mTOR | 0.64687 | -0.0252 | 0.3599 | 0.0411 | 0.3938 | 10.5271 | 0.97679 |
CAL-85-1 | Ceritinib | ALK | RTK | 0.74024 | -0.5961 | 0.3725 | 0.0586 | 0.9797 | 2.2143 | 0.9988 |
CAL-85-1 | Neratinib | EGFR/HER2 | RTK | 0.033863 | -0.3264 | 0.5379 | 0.1694 | 0.6592 | 0.072972 | 0.9766 |
CAL-85-1 | Tivantinib | MET | RTK | 0.19824 | -0.3263 | 0.5188 | 0.1982 | 1.5649 | 0.27534 | 0.99663 |
CAL-85-1 | Cediranib | VEGFR/cKIT | RTK | 2.4003 | -0.2379 | 0.1869 | 0.0514 | 1.1002 | 6.5151 | 0.99569 |
CAL-85-1 | Cabozantinib | VEGFR2/MET | RTK | 5.3386 | 0.1728 | 0.1229 | 0.0278 | 1.1624 | 13.7367 | 0.96943 |
HCC1143 | Abemaciclib | CDK4/6 | Cell cycle | 0.07025 | -0.0787 | 0.5407 | 0.0153 | 0.5300 | 0.09592 | 0.97963 |
HCC1143 | Palbociclib | CDK4/6 | Cell cycle | 0.27702 | 0.2820 | 0.2546 | -0.0033 | 0.9158 | 0.11143 | 0.98993 |
HCC1143 | AZD7762 | CHK1/2 | Cell cycle | 0.05422 | -0.3693 | 0.6563 | 0.2192 | 1.8612 | 0.067869 | 0.988 |
HCC1143 | Volasertib | PLK | Cell cycle | 0.0045882 | -0.3453 | 0.7290 | 0.2418 | 1.8336 | 0.005996 | 0.99928 |
HCC1143 | Dinaciclib | pan CDK | Cell cycle | 0.015148 | -0.2527 | 0.5451 | 0.1106 | 5.0000 | 0.016398 | 0.9989 |
HCC1143 | Cisplatin | Chemo | Chemotherapy | 0.83695 | 0.0754 | 0.3041 | 0.0403 | 1.3278 | 0.83273 | 0.96685 |
HCC1143 | Doxorubicin | Chemo | Chemotherapy | 0.0092688 | -0.2511 | 0.7180 | 0.1402 | 1.1622 | 0.012302 | 0.98917 |
HCC1143 | Taxol | Chemo | Chemotherapy | 0.0020688 | -0.3349 | 0.8388 | 0.3074 | 2.5955 | 0.0024565 | 0.99279 |
HCC1143 | Topotecan | Topo I | Chemotherapy | 0.0094142 | -0.4304 | 0.9040 | 0.3002 | 1.1711 | 0.013874 | 0.94725 |
HCC1143 | Etoposide | Topo II | Chemotherapy | 0.46267 | -0.1664 | 0.3837 | 0.1279 | 1.8259 | 0.55287 | 0.99758 |
HCC1143 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.13934 | 0.2573 | 0.4469 | 0.1044 | 0.5121 | 0.046932 | 0.96213 |
HCC1143 | Trametinib | MEK | MAPK/nRTK | 0.0088297 | -0.0225 | 0.5379 | 0.1187 | 0.5756 | 0.013291 | 0.99613 |
HCC1143 | Saracatinib | SRC | MAPK/nRTK | 3.0304 | 0.3881 | 0.2375 | 0.0437 | 0.4638 | 1.6973 | 0.97807 |
HCC1143 | ABT-737 | Bcl2/XL | Misc | 6.1992 | 0.3758 | 0.1027 | 0.0110 | 0.8672 | 8.5825 | 0.98522 |
HCC1143 | Vorinostat | HDAC | Misc | 0.91041 | -0.2533 | 0.2953 | 0.0977 | 1.9423 | 1.1249 | 0.99293 |
HCC1143 | Luminespib | HSP90 | Misc | 0.0039434 | -0.1922 | 0.7017 | 0.1659 | 3.6671 | 0.0042921 | 0.99512 |